Related Experiment Video
Updated: May 7, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Treatment for mild cognitive impairment: systematic review
Claudia Cooper1, Ryan Li, Constantine Lyketsos
1Claudia Cooper, MRCPsych, PhD, Ryan Li, BSc, Mental Health Sciences Unit, University College London, UK; Constantine Lyketsos, MD, MHS, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine and Johns Hopkins Bayview, Johns Hopkins Medicine, Baltimore, Maryland, USA; Gill Livingston, FRCPsych, MD, Mental Health Sciences Unit, University College London, UK.
Summary
No current interventions effectively slow cognitive decline in mild cognitive impairment (MCI). Further research is needed to identify effective treatments for this dementia precursor.
Area of Science:
- Neurology
- Gerontology
- Clinical Psychology
Background:
- Mild cognitive impairment (MCI) is increasingly prevalent and often precedes dementia.
- Effective strategies to prevent or slow MCI progression remain unknown.
Purpose of the Study:
- To systematically review randomized controlled trials (RCTs) of interventions for MCI.
- To evaluate the impact of interventions on cognitive, neuropsychiatric, functional, and global outcomes, quality of life, and dementia incidence.
Main Methods:
- A systematic review of 41 randomized controlled trials (RCTs) was conducted.
- Study validity was assessed using a checklist.
- Standardized outcomes were calculated, with a focus on placebo-controlled studies.
Main Results:
- Cholinesterase inhibitors showed no effect in reducing dementia incidence.
- Single trials indicated cognitive improvements with psychological group interventions, piribedil (dopamine agonist), and donepezil.
- Nicotine demonstrated attention improvement; Huannao Yicong showed equivocal cognitive and social functioning benefits.
Conclusions:
- No intervention demonstrated replicated efficacy in preventing dementia progression.
- Cholinesterase inhibitors and rofecoxib were found ineffective for dementia prevention.
- High-quality RCTs are necessary, with preliminary evidence supporting psychological interventions and piribedil.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...